Literature DB >> 9362191

Functional measurement of nonfibrotic hepatic mass in cirrhotic patients.

J C Hoefs1, F Wang, G Kanel.   

Abstract

OBJECTIVES: We have postulated that the perfused hepatic mass (PHM) can be estimated by quantitative (volumetric) liver spleen scan (QLSS) using single photon emission computed tomography assessment of sulfur colloid distribution between liver, spleen, and bone marrow. Thus, this parameter should correlate with the amount of functioning tissue in the liver. As a "gold standard" estimate of the nonfibrotic functioning hepatic mass, the weight of the liver at autopsy or transplant was corrected for the amount of scar tissue present. QLSS parameters were correlated with functional hepatic mass in 13 patients with advanced liver disease with liver available at transplant (8 patients) or autopsy (5 patients) who had prior QLSS.
METHODS: Greater than 1000 mm2 of a liver tissue was assessed histologically in all patients and from more than 2 regions of the liver in 9 of 13 patients. The total fibrosis score (TFS) (range, 0-17.5) was calculated as a semiquantitative estimate of hepatic fibrosis. The ratio of functioning tissue was calculated as (1 - TFS/20) and the amount of functioning tissue as the nonfibrotic weight (NFW): NFW = liver weight x (1--TFS/20). QLSS parameters were measured postprandially and 30 min after injection of 5 mCi of technetium Tc 99m sulfur colloid. Pixel and total counts from the liver, spleen, and bone marrow as well as organ length were measured. Liver/bone marrow index and liver/spleen index were calculated. The perfused hepatic mass (PHM) was defined as the mean of the liver/bone marrow index and liver/spleen index.
RESULTS: All patients had cirrhosis: alcoholic (1 patient), alcoholic with alcoholic hepatitis (1 patient), hepatitis B (3 patients), hepatitis C (6 patients), hepatitis C with hepatocellular carcinoma (1 patient), and primary sclerosing cholangitis (n = 1). The ratio of functioning tissue was 0.54 +/- 0.07; liver weight 1215 +/- 317 g; and NFW = 658 +/- 193 g. The PHM = 55 +/- 14. The PHM calculated from the QLSS correlated strongly with the NFW (functioning tissue) at autopsy/transplant: NFW = 13 PHM - 55; r = 0.9505; p < 0.0001).
CONCLUSIONS: In cirrhotic patients (a) we have confirmed that the sulfur colloid distribution by QLSS is determined by the perfused hepatic mass, and (b) the amount of functioning tissue can be precisely estimated by QLSS parameters.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9362191

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

1.  Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients.

Authors:  Stephen R Bowen; Jatinder Saini; Tobias R Chapman; Robert S Miyaoka; Paul E Kinahan; George A Sandison; Tony Wong; Hubert J Vesselle; Matthew J Nyflot; Smith Apisarnthanarax
Journal:  Radiother Oncol       Date:  2015-04-28       Impact factor: 6.280

2.  Clinical Utility of Biomarkers of Liver Fibrosis.

Authors:  Keyur Patel; Don C Rockey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

3.  Functional imaging of radiation liver injury in a liver metastasis patient: imaging and pathologic correlation.

Authors:  Tobias R Chapman; Asangi R Kumarapeli; Matthew J Nyflot; Stephen R Bowen; Raymond S Yeung; Hubert J Vesselle; Matthew M Yeh; Smith Apisarnthanarax
Journal:  J Gastrointest Oncol       Date:  2015-06

4.  Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.

Authors:  Gregory T Everson; Mitchell L Shiffman; John C Hoefs; Timothy R Morgan; Richard K Sterling; David A Wagner; Shannon Lauriski; Teresa M Curto; Anne Stoddard; Elizabeth C Wright
Journal:  Hepatology       Date:  2012-03-01       Impact factor: 17.425

5.  Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy.

Authors:  Gregory T Everson; John C Hoefs; Claus U Niemann; Kim M Olthoff; Robert Dupuis; Shannon Lauriski; Andrea Herman; Norah Milne; Brenda W Gillespie; Nathan P Goodrich; James E Everhart
Journal:  Liver Transpl       Date:  2013-03       Impact factor: 5.799

6.  Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C.

Authors:  John Carl Hoefs; Vikramjit S Aulakh; Bernard Joseph Ilagan
Journal:  Dig Dis Sci       Date:  2011-12-04       Impact factor: 3.199

7.  Factors affecting the quantitative liver-spleen scan in normal individuals.

Authors:  John C Hoefs; Muhammad Y Sheikh; Heather Guerrero; Norah Milne
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 8.  Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.

Authors:  Christopher H Crane; Eugene J Koay
Journal:  Cancer       Date:  2016-03-07       Impact factor: 6.860

9.  Role of Tc99m sulfur colloid scintigraphy in differentiating non-cirrhotic portal fibrosis from cirrhosis liver.

Authors:  Dhritiman Chakraborty; Hejjaji Venkataramarao Sunil; Bhagwant Rai Mittal; Anish Bhattacharya; Baljinder Singh; Yogesh Chawla
Journal:  Indian J Nucl Med       Date:  2010-10

10.  Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients.

Authors:  Stephen R Bowen; Tobias R Chapman; Joshua Borgman; Robert S Miyaoka; Paul E Kinahan; Iris W Liou; George A Sandison; Hubert J Vesselle; Matthew J Nyflot; Smith Apisarnthanarax
Journal:  EJNMMI Res       Date:  2016-06-27       Impact factor: 3.138

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.